Clinical Trials on Psoriasis Geographica in Czechia

Total 128 results

AbbVie

Active, not recruiting

A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy (KEEPsAKE 1)

Psoriatic Arthritis

United States, Argentina, Australia, Belgium, Bosnia and Herzegovina, Brazil, Bulgaria, Canada, Chile, Croatia, Czechia, Denmark, Estonia, Finland, Germany, Greece, Israel, Italy, Korea, Republic of, Latvia, Lithuania, Malaysia, Mexico and more
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety of Secukinumab in Psoriatic Arthritis and Axial Spondyloarthritis Patients With Active Enthesitis Including One Achilles Tendon Site (ACHILLES)

Psoriatic Arthritis | Enthesitis | Axial Spondyloarthritis

Germany, Spain, United Kingdom, Greece, Bulgaria, Italy, Czechia, Slovakia
Pfizer
Hospira, now a wholly owned subsidiary of Pfizer

Completed

Post-Marketing Use Of CT-P13 (Infliximab) For Standard Of Care Treatment Of Rheumatoid Diseases Who Are Naïve To Biologics Or Switched From Remicade (PERSIST)

Rheumatoid Arthritis | Psoriatic Arthritis | Ankylosing Spondylitis | Rheumatoid Diseases

Spain, Canada, Greece, United Kingdom, Germany, Bulgaria, Czechia
CSL Behring

Completed

Psoriatic Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to NSAIDs or Non-biologic Disease Modifying Anti-rheumatic Drugs (DMARDs) Therapy

Arthritis, Psoriatic

Italy, United States, Canada, Mexico, Poland, Spain, Germany, Czechia, Russian Federation, Australia, South Africa, Argentina, Hungary
Bausch Health Americas, Inc.

Terminated

Study of Efficacy, Safety and Effect on Radiographic Progression of Brodalumab in Subjects With Psoriatic Arthritis (AMVISION-1)

Psoriatic Arthritis

United States, Italy, Spain, Hungary, Belgium, Mexico, Poland, Switzerland, United Kingdom, Russian Federation, Canada, Greece, France, Bulgaria, Slovakia, Estonia, Czech Republic
Novartis Pharmaceuticals

Completed

Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Nail Psoriasis (TRANSFIGURE)

Moderate to Severe Nail Psoriasis

Germany, Belgium, Spain, United States, Australia, United Kingdom, Denmark, Czechia, Greece
Samsung Bioepis Co., Ltd.

Completed

A Study to Compare SB17 (Proposed Ustekinumab Biosimilar) to Stelara® in Subject With Moderate to Severe Plaque Psoriasis

Psoriasis | Moderate to Severe Plaque Psoriasis

Czechia, Estonia, Hungary, Korea, Republic of, Latvia, Lithuania, Poland, Ukraine
Biotest

Completed

Safety and Efficacy of Multiple Doses of BT061 in Patients With Moderate to Severe Chronic Plaque Psoriasis

Psoriasis Vulgaris

Czech Republic, Hungary
AbbVie

Active, not recruiting

A Study Comparing Upadacitinib (ABT-494) to Placebo in Participants With Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Biologic Disease Modifying Anti-Rheumatic Drug (bDMARD) (SELECT - PsA 2)

Psoriatic Arthritis

United States, Belgium, Brazil, Canada, Chile, Czechia, France, Greece, Hungary, Italy, Japan, Netherlands, New Zealand, Portugal, Puerto Rico, Spain, United Kingdom
Bristol-Myers Squibb

Active, not recruiting

A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs

Psoriatic Arthritis

Russian Federation, United States, Argentina, Australia, Brazil, Bulgaria, Chile, China, Colombia, Czechia, Finland, France, Hungary, Ireland, Italy, Mexico, Poland, Romania, Spain, Taiwan, United Kingdom
Janssen Research & Development, LLC

Completed

A Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis

Arthritis, Psoriatic

United States, Turkey, Malaysia, Czechia, Bulgaria, Poland, Russian Federation, Ukraine, Spain, Taiwan, Latvia, Estonia, Lithuania
AbbVie

Active, not recruiting

A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD) (SELECT - PsA 1)

Psoriatic Arthritis

United States, Argentina, Australia, Belarus, Belgium, Bosnia and Herzegovina, Brazil, Bulgaria, Canada, Chile, China, Colombia, Croatia, Czechia, Estonia, Germany, Greece, Hong Kong, Hungary, Ireland, Israel, Italy, Japan, Korea, Republic... and more
UCB BIOSCIENCES GmbH

Completed

Certolizumab Pegol in Subjects With Adult Onset Active and Progressive Psoriatic Arthritis

Arthritis, Psoriatic

Germany, United States, Argentina, Belgium, Brazil, Canada, Czechia, France, Hungary, Ireland, Italy, Mexico, Poland, Spain, United Kingdom
UCB Biopharma S.P.R.L.

Completed

An Efficacy and Safety Study of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO) (CIMPASI-1)

Psoriasis | Plaque Psoriasis

United States, Canada, Czechia, Germany, Hungary
UCB Biopharma SRL

Completed

A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Patients With Chronic Plaque Psoriasis (BE ABLE 2)

Chronic Plaque Psoriasis

United States, Canada, Czechia, Hungary, Japan, Poland
UCB Biopharma S.P.R.L.
Parexel

Completed

Study to Evaluate Safety and Efficacy of Different Doses of Bimekizumab in Patients With Chronic Plaque Psoriasis (BE ABLE 1)

Chronic Plaque Psoriasis

United States, Canada, Czechia, Hungary, Japan, Poland
Janssen Research & Development, LLC

Completed

A Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti -Tumor Necrosis Factor (TNF) Alpha Agent(s) (Discover-1)

Arthritis, Psoriatic

United States, Canada, Taiwan, Hungary, Malaysia, Germany, Czechia, Korea, Republic of, Russian Federation, Spain, Australia, Ukraine, Poland
Momenta Pharmaceuticals, Inc.

Completed

Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis

Psoriasis | Chronic Plaque Psoriasis

United States, Poland, Canada, Czechia, Estonia, Germany, Slovakia, Bulgaria, Latvia
Janssen Research & Development, LLC

Recruiting

A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease (STAR)

Arthritis, Psoriatic

Italy, Germany, Taiwan, United States, Malaysia, Turkey, Georgia, Canada, Hong Kong, Portugal, Denmark, Israel, Philippines, Thailand, Bulgaria, Australia, Czechia, Hungary, Poland, Russian Federation, Ukraine, Spain, Argentina, United... and more
Fresenius Kabi SwissBioSim GmbH
Merck KGaA, Darmstadt, Germany

Completed

MSB11022 in Moderate to Severe Chronic Plaque Psoriasis (AURIEL-PsO)

Psoriasis | Moderate to Severe Plaque Psoriasis | Plaque Type Psoriasis

United States, Canada, Czechia, Hungary, Russian Federation, Bulgaria, Mexico, United Kingdom, Poland, Germany, Estonia, France
UCB Biopharma SRL

Completed

A Study to Assess How Well Certolizumab Pegol Works in Patients With Moderate to Severe Plaque Psoriasis as Part of Routine Clinical Practice (CIMREAL)

Plaque Psoriasis

Belgium, Canada, Czechia, France, Germany, Greece, Italy, Spain, United Kingdom
Alumis Inc

Completed

A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Plaque Psoriasis

Plaque Psoriasis

United States, Canada, Czechia
Novartis Pharmaceuticals

Completed

Study to Assess the Long-term Safety, Tolerability, Efficacy of Secukinumab in Pediatric Patients of Age 6 to <18 Years, With Moderate to Severe Plaque Psoriasis

Moderate to Severe Chronic Plaque-type Psoriasis

Belgium, Spain, Russian Federation, Germany, United States, Czechia, Peru, Poland, Estonia
Galapagos NV
Gilead Sciences

Completed

Study to Evaluate the Effect of Filgotinib on Semen Parameters in Adult Males With Active Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, or Non-radiographic Axial Spondyloarthritis (MANTA-RAy)

Rheumatoid Arthritis | Psoriatic Arthritis | Ankylosing Spondylitis | Non-Radiographical Axial Spondyloarthritis

Bulgaria, Ukraine, Poland, Estonia, Czechia, Georgia, Latvia, Spain
DICE Therapeutics, Inc., a wholly owned subsidiary...

Active, not recruiting

A Study to Evaluate the Efficacy and Safety of DC-806 in Participants With Moderate to Severe Plaque Psoriasis (Illuminate)

Plaque Psoriasis

Canada, Hungary, Germany, Spain, United States, Poland, United Kingdom, Czechia
Pfizer

Completed

Study Evaluating Etanercept for the Treatment of Moderate to Severe Psoriasis (PRISTINE)

Psoriasis | Plaque Psoriasis

Spain, Taiwan, Germany, Korea, Republic of, Belgium, Greece, Hungary, Argentina, Austria, Czech Republic, Italy, Mexico, Thailand
Pfizer

Completed

Open-Label Extension Study Of Tofacitinib In Psoriatic Arthritis (OPAL BALANCE)

Arthritis, Psoriatic

Belgium, United States, Canada, Spain, Australia, Taiwan, Czechia, Hungary, Germany, Mexico, Poland, Russian Federation, Slovakia, United Kingdom, Brazil, Bulgaria
Janssen Research & Development, LLC

Recruiting

Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent (SOLSTICE)

Arthritis, Psoriatic

Turkey, United States, Australia, Russian Federation, Ukraine, Puerto Rico, Spain, Israel, Hungary, Poland, Bulgaria, Malaysia, Argentina, Czechia
Janssen Research & Development, LLC

Recruiting

A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX)

Arthritis, Psoriatic

Israel, United States, Germany, Taiwan, Korea, Republic of, Malaysia, China, Georgia, Poland, Spain, Philippines, Hungary, Italy, Canada, Bulgaria, Russian Federation, Serbia, Slovenia, Bosnia and Herzegovina, Greece, Ukraine, Cze... and more
Eli Lilly and Company

Completed

Study of Ixekizumab (LY2439821) in Children 6 to Less Than 18 Years With Moderate-to-Severe Plaque Psoriasis (Ixora-peds)

Plaque Psoriasis

United States, Spain, Puerto Rico, Czechia, Canada, Germany, France, Poland, Hungary, Mexico, Russian Federation, Argentina, Netherlands
Apellis Pharmaceuticals, Inc.

Active, not recruiting

An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD (GALE)

Geographic Atrophy Secondary to Age-related Macular Degeneration

United States, Netherlands, France, Israel, Germany, United Kingdom, Canada, Czechia, Australia, Spain, Italy, Argentina, Brazil, New Zealand, Poland
AbbVie (prior sponsor, Abbott)

Completed

Effectiveness of Adalimumab (HUMIRA®) in the Treatment of Scalp and Nail Affection in Patients With Moderate to Severe Plaque Psoriasis in Routine Clinical Practice

Moderate to Severe Plaque Psoriasis

Czech Republic, Estonia, Hungary, Israel, Romania, Slovakia, Slovenia, Ukraine
UCB Biopharma S.P.R.L.

Completed

Efficacy and Safety Study of Certolizumab Pegol (CZP) Versus Active Comparator and Placebo in Subjects With Plaque Psoriasis (PSO) (CIMPACT)

Psoriasis | Plaque Psoriasis

United States, Bulgaria, Czechia, France, Germany, Hungary, Netherlands, Poland, United Kingdom
Eli Lilly and Company

Completed

A Study Comparing Different Dosing Regimens of Ixekizumab (LY2439821) in Participants With Moderate to Severe Plaque Psoriasis (IXORA-P)

Plaque Psoriasis

Argentina, Puerto Rico, United States, Australia, Taiwan, Japan, Hungary, Korea, Republic of, Mexico, Germany, Poland, Romania, Czechia, Canada
Novartis Pharmaceuticals

Completed

Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis (CLARITY)

Plaque Psoriasis

United States, Hungary, Malaysia, Czechia, Korea, Republic of, Guatemala, Poland, Vietnam, Canada, Iceland, Slovakia
LEO Pharma

Recruiting

Adjusted Brodalumab Dose Compared With Standard Brodalumab Dose in Subjects With Moderate-to-severe Plaque Psoriasis and ≥120 kg Body Weight (ADJUST)

Psoriasis Vulgaris

Belgium, Italy, Spain, Germany, Czechia, Greece, United Kingdom, France, Hungary, Poland, Netherlands
Amgen

Completed

Double-Blind, Randomized, Placebo-controlled Comparison of CC-10004 in Subjects With Moderate to Severe Plaque Type Psoriasis (PSOR-003)

Psoriasis

Canada, Czechia, Germany
IVERIC bio, Inc.

Completed

Zimura in Participants With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Macular Degeneration | Geographic Atrophy

United States, Israel, Estonia, Hungary, Latvia, Czechia, Croatia
Novartis Pharmaceuticals

Completed

4 Year Extension Study of Efficacy and Safety of Secukinumab in Patients With Moderate to Severe Chronic Plaque-type Psoriasis

Moderate to Severe Chronic Plaque-Type Psoriasis

United States, Germany, Japan, Bulgaria, Czechia, Singapore, Switzerland, United Kingdom, Italy, France, Vietnam, Poland, Slovakia, Austria, Canada
Novartis Pharmaceuticals

Completed

Plaque Psoriasis Efficacy and Safety With Secukinumab (OPTIMISE)

Plaque Psoriasis

Germany, Belgium, Spain, Croatia, Czechia, Greece, Hungary, Russian Federation, Netherlands, Austria, France, Switzerland, Israel, United Kingdom, Italy, Lithuania, Sweden, Bulgaria, Denmark, Finland, Portugal, Slovakia, Poland, Latvia
Sandoz
Hexal AG

Completed

Study to Demonstrate Equivalent Efficacy and to Compare Safety of Biosimilar Etanercept (GP2015) and Enbrel (EGALITY)

Chronic Stable Plaque Psoriasis

Germany, Romania, Bulgaria, Czech Republic, Estonia, Hungary, Poland, Russian Federation, Slovakia, South Africa, Ukraine, United Kingdom
Ionis Pharmaceuticals, Inc.

Active, not recruiting

GOLDEN STUDY: A Study to Assess Safety and Efficacy of Multiple Doses of IONIS-FB-LRx in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD)

Macular Degeneration | Geographic Atrophy

United States, Spain, Australia, Austria, Canada, Czechia, Netherlands, New Zealand, Poland
IVERIC bio, Inc.

Completed

A Phase 3 Safety and Efficacy Study of Intravitreal Administration of Zimura (Complement C5 Inhibitor)

Macular Degeneration | Geographic Atrophy

United States, Spain, France, Germany, Austria, Belgium, Israel, Poland, Canada, Italy, Estonia, Australia, United Kingdom, Hungary, Argentina, Brazil, Colombia, Croatia, Czechia, Latvia
Bausch Health Americas, Inc.

Terminated

P3 Study Brodalumab in Treatment of Moderate to Severe Plaque Psoriasis (AMAGINE-2)

Moderate to Severe Plaque Psoriasis

United States, Austria, France, Poland, Australia, Czechia, Canada, Hungary, Portugal, Spain, Netherlands
Astellas Pharma Global Development, Inc.

Active, not recruiting

Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy

Age-Related Macular Degeneration | Geographic Atrophy

United States, Italy, Latvia, France, Israel, Germany, Spain, Hungary, Brazil, Canada, Argentina, Colombia, Croatia, Australia, Austria, Belgium, Czechia
Abbott

Completed

Adalimumab in Combination With Topical Treatment (Calcipotriol/Betamethasone) in Subjects With Moderate to Severe Psoriasis and Insufficient Response to Classic Systemic Treatment (BELIEVE)

Chronic Plaque Psoriasis

Belgium, Denmark, France, Germany, Spain, Sweden, Switzerland, Finland, Turkey, Italy, Czech Republic, Austria, Netherlands, United Kingdom, Greece
Novartis Pharmaceuticals

Completed

Efficacy and Safety of 2 Secukinumab Regimens in 90kg or More Weight Group With Moderate/Severe Chronic Plaque Psoriasis

Moderate to Severe Chronic Plaque-type Psoriasis

United States, Hungary, Italy, Russian Federation, Germany, Czechia, Canada
Janssen Research & Development, LLC

Recruiting

A Study to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

Geographic Atrophy

Netherlands, United States, Belgium, Italy, Germany, United Kingdom, Denmark, Spain, Czechia, Switzerland, Turkey, Canada, Hungary, Portugal, Australia, Sweden, Poland
AbbVie

Completed

Chronic Plaque Psoriasis (Ps) Registry

Chronic Plaque Psoriasis

United States, Austria, Canada, Czechia, Denmark, France, Germany, Greece, Ireland, Netherlands, Puerto Rico, Spain, Sweden, United Kingdom
Amgen

Active, not recruiting

A Long-term Extension Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque Psoriasis

Psoriasis

Belgium, Spain, United States, Czechia, Italy, Russian Federation, Canada, France, Israel

Clinical Trials on Psoriasis Geographica in Czechia

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Taiwan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations